We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical firms increased wholesale prices for brand drugs most commonly used by Americans 50 and older at more than twice the rate of inflation from April 2004 to March 2005, according to an AARP report.
The European Union (EU) has fined AstraZeneca $73 million for artificially inflating the price of its ulcer treatment Losec and misusing the EU’s patent system to delay entry of generic competition for the drug.
Clinical investigators are increasingly turning to industry sponsors to help them cover “hidden” trial costs — such as prestudy services — that are starting to eat away at research institutions’ operating budgets.
Merck is taking a new approach in its latest advertising campaign, which, instead of promoting a specific product, touts the firm’s research efforts and pharmaceutical access programs.
Grassroots campaigns that explain the value of medicines through the eyes of patients and rank-and-file drug firm employees can help the pharmaceutical industry overcome its negative reputation, according to communications executives.
Patients with chronic conditions are having more trouble affording their prescription drugs than patients without such conditions, according to a new study.
A bipartisan group of state legislators has urged the FTC to stop defending the pharmaceutical benefit manager (PBM) industry and to crack down on “deceptive and fraudulent practices” utilized by PBMs.
A House Democrat wants the Bush Administration to conduct a study on pharmaceutical R&D costs, noting that the estimated costs of bringing a new drug to market may be inflated by as much as 750 percent.
The estimated costs of bringing a new drug to market may be inflated by as much as 750 percent, according to a House Democrat who has called on the Bush Administration to conduct a study on pharmaceutical R&D costs.